Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is one of the...

• Russell 3000.

Aurinia Pharmaceuticals is a company listed under the stock ticker AUPH (US).

View the org chart displaying its 19 main executives

Most searched biographies at Aurinia Pharmaceuticals

• Peter Greenleaf, Chief Executive Officer and Director
• Daniel Billen, Director
• David Jayne, Director

Popular executive movements at Aurinia Pharmaceuticals

• Robert Foster has joined the company as Director  (posted on September 22 2023).
• Karen Smith has joined the company as Director  (posted on August 22 2023).
• Jeffrey Bailey has joined the company as Director  (posted on August 22 2023).

Create your alert
to follow the executive moves at Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has 1,863 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Aurinia Pharmaceuticals

• Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
• UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
• Aurinia to Participate in Upcoming Investor Healthcare Conferences
• Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
• Press Releases
• Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
• Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
• Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
• Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
• Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
• View more press releases Close

Social media about Aurinia Pharmaceuticals

• Aurinia Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Aurinia Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Peter Greenleaf

Call Aurinia Pharmaceuticals at +1 780...

View the org chart

Register to receive your alert

Report an error